Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Stomach Neoplasms × Cetuximab × Clear all
NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Tizona Therapeutics, Inc

Phase 1 Recruiting
240 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT00397384 2015-09-30

Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer

National Cancer Institute (NCI)

Phase 1 Completed
43 enrolled
CNSGastrointestinalHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Tongue Neoplasms, Esthesioneuroblastoma, Olfactory, Gastrointestinal Stromal Tumors